Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07682129
PHASE2

Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Sponsor: Entrada Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This is a study of investigational medicines ENTR-601-44 and ENTR-601-45 designed to evaluate the long-term safety and tolerability of study drugs in participants with Duchenne muscular dystrophy (DMD). The investigational medicines are currently being investigated in multiple ascending dose parent studies. After participants complete their respective parent study, there is a need to understand the effects of long-term administration of ENTR-601-44 and ENTR-601-45. Participants enrolling in this study will begin this long-term extension (LTE) study at the dose level they received upon completion of the parent study with possible dose escalation in the LTE study based on emerging safety and efficacy data from the parent studies. Participants will: * Receive study treatment in the form of multiple intravenous (IV) infusions (slow injections) into a vein over the course of several weeks * Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, and excersice tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a results of the study drug. Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.

Official title: A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Key Details

Gender

MALE

Age Range

4 Years - 20 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2026-08

Completion Date

2032-03

Last Updated

2026-07-02

Healthy Volunteers

No

Interventions

DRUG

ENTR-601-44

ENTR-601-44 intravenous infusion

DRUG

ENTR-601-45

ENTR-601-45 intravenous infusion

Locations (17)

University Hospital Gent

Ghent, Belgium

UZ Leuven

Leuven, Belgium

Centre Hospitalier Régional de la Citadelle

Liège, Belgium

IRCCS Ospedale San Raffaele

Milan, Italy

Fondazione Serena Onlus - Centro Clinico NeMO Milano

Milan, Italy

Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

Roma, Italy

Ospedale Pediatrico Bambino Gesu

Rome, Italy

Leids Universitair Medisch Centrum

Leiden, Netherlands

Stichting Radboud Universitair Medisch Centrum

Nijmegen, Netherlands

Hospital Universitario Vall d'Hebron

Barcelona, Spain

Hospital Sant Joan de Deu

Barcelona, Spain

Leeds General Infirmary

Leeds, United Kingdom

Alder Hey Children's NHS Foundation Trust

Liverpool, United Kingdom

Great Ormond Street Hospital for Children

London, United Kingdom

Royal Manchester Children's Hospital

Manchester, United Kingdom

Freeman Hospital

Newcastle upon Tyne, United Kingdom

Oxford University Hospitals NHS Foundation Trust

Oxford, United Kingdom